Literature DB >> 9528820

Estimation of the effect of neutropenia on rates of clinical bacteraemia in HIV-infected patients.

J Caperna1, R E Barber, J G Toerner, W C Mathews.   

Abstract

A retrospective cohort study was conducted to quantitate the relationship between neutropenia and rates of clinical bacteraemia among adults with HIV infection receiving medical care at one institution between 1991-5. The primary exposure, absolute neutrophil count (ANC), was summarized as mean ANC within a given week, using a five-level stratification (reference > 1000/microl). ANC stratum-specific rates of bacteraemia were calculated, by organism type. Linear trend tests were performed to assess dose-response relationship between neutropenia and rates of bacteraemia. The cohort included 1645 patients contributing 26,785 patients-weeks and 191 episodes of bacteraemia. The unadjusted effect of neutropenia was most evident for bacteraemia due to E. coli (RR 3.4), Klebsiella pneumoniae (RR 16.7), and P. aeruginosa (RR 10.4). For bacteraemia due to any of these three organisms (47 episodes), with reference ANC > 1000/microl, relative rates were: 751-1000/microl, 1.12; 501-750/microl, 2.11; 251-500/microl, 13.58; 0-250/microl, 21.89.

Entities:  

Mesh:

Year:  1998        PMID: 9528820      PMCID: PMC2809351          DOI: 10.1017/s095026889700842x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  2 in total

1.  Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey.

Authors:  R Manfredi; A Nanetti; M Ferri; F Chiodo
Journal:  Eur J Epidemiol       Date:  2000-02       Impact factor: 8.082

2.  Incidence of Severe Neutropenia in HIV-Infected People Starting Antiretroviral Therapy in West Africa.

Authors:  Charline Leroi; Eric Balestre; Eugene Messou; Albert Minga; Adrien Sawadogo; Joseph Drabo; Moussa Maiga; Marcel Zannou; Moussa Seydi; Francois Dabis; Antoine Jaquet
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.